Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients

[1]  G. Dranitsaris,et al.  Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors , 2016, Supportive Care in Cancer.

[2]  C. Loprinzi,et al.  Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double-blind, placebo-controlled trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  F. D. De Braud,et al.  Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies , 2015, Supportive Care in Cancer.

[4]  P. Gascón,et al.  Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study , 2015, Supportive Care in Cancer.

[5]  T. Furuhata,et al.  Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron , 2015, Cancer science.

[6]  Y. Hirashima,et al.  Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial , 2014, Supportive Care in Cancer.

[7]  A. Molassiotis,et al.  Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. , 2014, Journal of pain and symptom management.

[8]  N. Masumori,et al.  Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. , 2014, Journal of pain and symptom management.

[9]  D. Warr.  Prognostic factors for chemotherapy induced nausea and vomiting. , 2014, European journal of pharmacology.

[10]  Shiying Yu,et al.  Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study , 2014, Supportive Care in Cancer.

[11]  Myung Ah Lee,et al.  Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries , 2014, Supportive Care in Cancer.

[12]  Shiying Yu,et al.  Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines , 2014, Supportive Care in Cancer.

[13]  B. Han,et al.  Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice , 2014, Supportive Care in Cancer.

[14]  K. Kubota,et al.  Risk factors of chemotherapy‐induced nausea and vomiting: Index for personalized antiemetic prophylaxis , 2013, Cancer science.

[15]  M. Aapro,et al.  Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. , 2013, Cancer treatment reviews.

[16]  K. Eguchi,et al.  Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  G. Dranitsaris,et al.  Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. , 2012, The journal of supportive oncology.

[18]  Scott E. Smith,et al.  Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  A. Molassiotis,et al.  The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Hesketh,et al.  Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy , 2008, Supportive Care in Cancer.

[22]  E. Bayliss,et al.  Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study , 2011, Supportive Care in Cancer.

[23]  D. Warr,et al.  Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy , 2011, Supportive Care in Cancer.

[24]  A. Molassiotis,et al.  Antiemetic research: future directions , 2011, Supportive Care in Cancer.

[25]  N. Aaronson,et al.  Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study , 2011, Supportive Care in Cancer.

[26]  M. Dodd,et al.  The relationship of chemotherapy-induced nausea to the frequency of pericardium 6 digital acupressure. , 2010, Oncology nursing forum.

[27]  P. Jean-Pierre,et al.  An exploratory study on the effects of an expectancy manipulation on chemotherapy-related nausea. , 2010, Journal of pain and symptom management.

[28]  L. Cavanna,et al.  Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial , 2010, Supportive Care in Cancer.

[29]  M. Aapro,et al.  Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  M. Kris,et al.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  M. Aapro,et al.  Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy , 2010, Supportive Care in Cancer.

[32]  L. Colman,et al.  Effect of a nausea expectancy manipulation on chemotherapy-induced nausea: a university of Rochester cancer center community clinical oncology program study. , 2008, Journal of pain and symptom management.

[33]  A. Molassiotis,et al.  A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre , 2008, Supportive Care in Cancer.

[34]  H. Rugo,et al.  Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial. , 2007, Oncology nursing forum.

[35]  C. Clements,et al.  Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. , 2007, Journal of pain and symptom management.

[36]  Jiyeon Lee,et al.  Chemotherapy‐induced Nausea/Vomiting and Functional Status in Women Treated for Breast Cancer , 2005, Cancer nursing.

[37]  G. Morrow,et al.  Patient expectation is a strong predictor of severe nausea after chemotherapy , 2004, Cancer.

[38]  A. Molassiotis,et al.  The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial , 2002, Supportive Care in Cancer.

[39]  A. Molassiotis,et al.  Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients , 2002, Supportive Care in Cancer.

[40]  M. Martín,et al.  The severity and pattern of emesis following different cytotoxic agents. , 1996, Oncology.

[41]  J. Sullivan,et al.  Decreased cisplatin-induced nausea and vomiting with chronic alcohol ingestion. , 1983, The New England journal of medicine.